Literature DB >> 2357356

Retinopathy of prematurity: screening and optimal use of the ophthalmologist's time.

B A Darlow1, R S Clemett.   

Abstract

In recent years it has been standard practice to recommend that indirect ophthalmoscopy be carried out between six and nine weeks of age in very low birthweight infants to screen for the presence of retinopathy of prematurity (ROP). Following this recommendation we examined 85 infants over a two-year period. Acute ROP occurred in 29 (34%), and two (2.4%) developed cicatricial disease. One-third of infants were initially examined slightly earlier or later than the strict six to nine week limits, but all except three infants were examined between 35 and 42 weeks gestation. One infant born at 26 weeks gestation, was examined 'too late' in that she had stage 4 disease when first seen at 11 weeks of age. Recent information on the natural history of ROP, and confirmation of the efficacy of treatment with cyotherapy, suggested that the timing of an initial screening examination for ROP needed reassessment. From our experience and a review of the literature we recommended that infants of less than 1000 g birthweight or less than 28 weeks gestation have an initial examination at six weeks of age; for infants of 1000 to 1250 g birthweight or 28 to 30 weeks gestation examination continue to be at six to nine weeks of age; and for infants of more than 1250 g birthweight or 31 weeks gestation screening at six to nine weeks of age is only necessary if the infant has had an unstable course or prolonged oxygen requirements. Such a protocol would not place too great a burden on ophthalmological services and would direct efforts towards the group of infants most at risk of severe visual handicap.

Entities:  

Mesh:

Year:  1990        PMID: 2357356     DOI: 10.1111/j.1442-9071.1990.tb00583.x

Source DB:  PubMed          Journal:  Aust N Z J Ophthalmol        ISSN: 0814-9763


  9 in total

1.  The optimum time to employ telephotoscreening to detect retinopathy of prematurity.

Authors:  K G Yen; D Hess; B Burke; R A Johnson; W J Feuer; J T Flynn
Journal:  Trans Am Ophthalmol Soc       Date:  2000

2.  Outcomes for high risk New Zealand newborn infants in 1998-1999: a population based, national study.

Authors:  A E Cust; B A Darlow; D A Donoghue
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2003-01       Impact factor: 5.747

3.  Improved outcomes for very low birthweight infants: evidence from New Zealand national population based data.

Authors:  B A Darlow; A E Cust; D A Donoghue
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2003-01       Impact factor: 5.747

4.  Variation in rates of severe retinopathy of prematurity among neonatal intensive care units in the Australian and New Zealand Neonatal Network.

Authors:  B A Darlow; J L Hutchinson; J M Simpson; D J Henderson-Smart; D A Donoghue; N J Evans
Journal:  Br J Ophthalmol       Date:  2005-12       Impact factor: 4.638

5.  Vitamin C supplementation in very preterm infants: a randomised controlled trial.

Authors:  B A Darlow; H Buss; F McGill; L Fletcher; P Graham; C C Winterbourn
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2005-03       Impact factor: 5.747

6.  Retinopathy of prematurity: A systematic review of the literature.

Authors: 
Journal:  Paediatr Child Health       Date:  1998-05       Impact factor: 2.253

7.  Long term follow up of premature infants: detection of strabismus, amblyopia, and refractive errors.

Authors:  N E Schalij-Delfos; M E de Graaf; W F Treffers; J Engel; B P Cats
Journal:  Br J Ophthalmol       Date:  2000-09       Impact factor: 4.638

8.  Retinopathy of prematurity in infants with late retinal examination.

Authors:  S Zeinab Mousavi; Reza Karkhaneh; Mohammad Riazi-Esfahani; Mohammad-Reza Mansouri; Ramak Roohipoor; Leila Ghalichi; Malihe Kadivar; Mehdi Nili-Ahmadabadi; Fatemeh Naieri
Journal:  J Ophthalmic Vis Res       Date:  2009-01

9.  Deep Learning Algorithm for Automated Diagnosis of Retinopathy of Prematurity Plus Disease.

Authors:  Zachary Tan; Samantha Simkin; Connie Lai; Shuan Dai
Journal:  Transl Vis Sci Technol       Date:  2019-12-02       Impact factor: 3.283

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.